Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Retained Earnings (2018 - 2025)

10x Genomics (TXG) has disclosed Retained Earnings for 8 consecutive years, with $225000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.02% to $225000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $225000.0 through Dec 2025, up 100.02% year-over-year, with the annual reading at $225000.0 for FY2025, 100.02% up from the prior year.
  • Retained Earnings hit $225000.0 in Q4 2025 for 10x Genomics, up from $138000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $225000.0 in Q4 2025 to a low of -$1.5 billion in Q1 2025.
  • Historically, Retained Earnings has averaged -$629.7 million across 5 years, with a median of -$845.5 million in 2021.
  • Biggest five-year swings in Retained Earnings: surged 473.08% in 2021 and later plummeted 1887045.83% in 2022.
  • Year by year, Retained Earnings stood at -$863.3 million in 2021, then fell by 19.23% to -$1.0 billion in 2022, then surged by 99.96% to -$429000.0 in 2023, then plummeted by 341869.0% to -$1.5 billion in 2024, then skyrocketed by 100.02% to $225000.0 in 2025.
  • Business Quant data shows Retained Earnings for TXG at $225000.0 in Q4 2025, $138000.0 in Q3 2025, and $220000.0 in Q2 2025.